Mark Anderson, MD, PhD, and his colleagues have discovered a distinctive type of immune cell called an eTAC, which puts a damper on immune responses and could eventually lead to more effective treatments for autoimmune diseases including type 1 diabetes.
An experimental drug that has been studied for nearly 20 years continues to show effectiveness in about half of the patients who participated in a recent phase 2 clinical trial. The drug, Teplizumab -- also known as anti CD3 -- is designed to block the advance of Type 1 Diabetes in its earliest stages.
Four prevention trials are currently under way at dozens of sites around the country, including both Stanford and UCSF. Click here to read the article.
This month, Dean Schillinger, MD, was awarded the 2013 Public Health Communications Research Award by the American Public Health Association (APHA). The APHA Everett Rogers Award is given to an individual who has made an outstanding contribution to advancing the study and/or practice of public health communication. Dr Schillinger, Chief of the UCSF Division of General Internal Medicine at SF General Hospital, is widely recognized for his seminal work in the field of health literacy.
RNA specialist, Michael McManus, PhD, received an NIH grant to explore and enhance our understanding of a recently discovered cell-to-cell messaging process called extracellular (outside the cell) RNA communication -- exRNA. Dr. McManus will explore basic exRNA biology and develop tools and technologies that apply new knowledge about exRNA to the research, diagnosis and treatment of diseases.
Feroz Papa, MD, PhD, was named a 2013 Harrington Scholar-Innovator by the Harrington Discovery Institute’s Scientific Advisory Board from a field of more than 130 applicants from 53 institutions. Dr.
World transplant and diabetes leaders convened in Monterey at the International Pancreas and Islet Transplantation Association (IPITA) to discuss advances in islet and pancreas transplantation as superior therapies for treating type 1 diabetes.
A drug designed to block the advance of type 1 diabetes in its earliest stages is strikingly effective in the phase 2 clinical trial, according to researchers at the University of California, San Francisco. Click here to read the full story.
A new Diabetes Center study highlights the potential importance of the vast majority of human DNA that lies outside of genes within the cell. Faculty member Michael McManus, PhD, graduate student Ian Vaughn, and postdoctoral fellow Matthew Hangauer, PhD, identified thousands of previously unknown, unique RNA sequences by looking at which regions of the genome are converted into RNA. RNA is a molecule that increasingly is being found to play myriad important roles within cells.
Shingo Kajimura, PhD, was named a 2013 Pew Scholar in the Biomedical Sciences which provides flexible funding to early-career scientists who are pursuing the most promising, but untried, avenues for scientific breakthroughs.
The UCSF Pediatric Diabetes Program led by Steve Gitelman, MD, has made progress in altering the course of type 1 diabetes. Through various screening tests, we are now able to identify relatives at risk for developing type 1 diabetes. For those at risk, there are currently three prevention trials that seek to prevent or delay the onset of disease.
Over the next 25 years, the number of Americans with diabetes is expected to double, and the economic costs of diabetes will almost triple. The need for a cure is urgent. In the Diabetes Center at UCSF, we believe that innovative, collaborative research is the answer. Through communication and a spirit of common purpose, our team of internationally renowned scientists and physicians is solidly united in the search for improved treatments and a cure.
We are proud to announce that Greg Ku, MD, PhD will join both our research and clinical care teams as Assistant Professor in the Diabetes Center and as a member of the Division of Endocrinology and Metabolism in the Department of Medicine.